Compare JQC & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JQC | IRWD |
|---|---|---|
| Founded | 2003 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 705.1M | 713.8M |
| IPO Year | N/A | 2009 |
| Metric | JQC | IRWD |
|---|---|---|
| Price | $4.76 | $4.43 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 612.6K | ★ 1.8M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 11.13% | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | N/A | ★ 0.55 |
| Revenue | N/A | ★ $298,276,000.00 |
| Revenue This Year | N/A | $57.95 |
| Revenue Next Year | N/A | $4.39 |
| P/E Ratio | ★ N/A | $8.02 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $4.62 | $1.05 |
| 52 Week High | $5.49 | $5.78 |
| Indicator | JQC | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 44.08 | 55.93 |
| Support Level | $4.69 | $3.85 |
| Resistance Level | $4.88 | $4.53 |
| Average True Range (ATR) | 0.03 | 0.17 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 16.67 | 83.16 |
Nuveen Credit Strategies Income Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. The fund meets its investment objectives by investing its managed assets in senior secured and second lien loans, and its managed assets across the capital structure of companies (including equity securities) with a primary emphasis on high yield bonds, convertible securities and other forms of income-producing securities.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.